India’s Health Ministry proposes draft amendments to drug rules to bring antimicrobials under tighter regulatory oversight. The changes would include antimicrobials within the definition of “new drug” in the New Drugs and Clinical Trials Rules, 2019. The ministry also proposes a separate licensing pathway for wholesale activities involving bulk drugs, including new forms for wholesale sale, according to the draft notifications described by outlets.

The proposal is linked to concerns over antimicrobial resistance. One draft would require manufacturers of antimicrobials to obtain permission from the Central Licensing Authority before applying for a State licence. Other reporting focuses on the scope of the amendment and the specific mechanism for updating the regulatory definition, including reference to the draft gazette notification dated November 6.

Across coverage, both outlets describe the same set of rule changes and rationale, but they emphasize different angles: one highlights the operational licensing steps and wholesale documentation, while the other foregrounds the legal inclusion of antimicrobials in the “new drug” definition.